Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAIC + Donafenib + Sintilimab for Resectable HCC
NCT06812039Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sintilimab and donafenib in hepatocellular carcinoma (HCC) (3 arms), sponsored by Fudan University. Primary endpoint: 1-year Recurrence-Free Survival Rate at 24 months. Started Jan 2025; status: recruiting.
02
Drugs
sintilimabdonafenib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06812039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06812039.